Main Article Content
Diabetes mellitus (DM) type 2 in clinical practice is often associated with non-alcoholic fatty liver disease (NAFLD), which has a number of clinical and morphological forms and develops in patients who do not abuse alcohol. The combination of DM type 2 and NAFLD is associated not only with a high risk of developing liver cirrhosis and hepatocellular carcinoma in these patients. Although all aspects of the etiology of NAFLD is not fully known, it is points to the role of insulin resistance in its development. This concept has facilitated a number of clinical studies using metformin as the insulin sensitizer in insulin-resistant patients with NAFLD. The findings emphasize the importance of metformin in the treatment of NAFLD in combination with a hypocaloric diet and the control of body weight. It is also reported about other tissue effects of metformin in NAFLD.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Кондратьева Л.В. Бигуаниды в терапии сахарного диабета / Под ред. А.С. Аметова. — М.: Планида, 2013. — 48 с.
Урбанович А.М. Неалкогольний стеатогепатит у пацієнтів із цукровим діабетом 2-го типу: сучасний погляд на проблему / А.М. Урбанович // Міжнародний ендокринологічний журнал. — 2009. — № 2 (20). — С. 38-42.
Nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, 2012.
Mazza A., Fruci B., Garinis G.A. et al. The role of metformin in the management of NAFLD // Experimental Diabetes Research. — 2012. — http://dx.doi.org/10.1155/2012/716404
Loria P., Lonardo A., Bellentani S. et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question // Nutrition Metabolism Cardiovascular Diseases. — 2007. — Vol. 17 (9). — P. 684-698.
Socha P., Horvath A., Vajro P. et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review // Journal of Pediatric Gastroenterology and Nutrition. — 2009. — Vol. 48 (5). — P. 587-596.
Hamaguchi M., Kojima T., Takeda N. et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease // Annals of Internal Medicine. — 2005. — Vol. 143 (10). — P. 722-728.
Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis // Annual Review of Pathology. — 2010. — Vol. 5. — P. 145-171.
Garinis G.A., Fruci B., Mazza A. et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study // International Journal of Obesity. — 2010. — Vol. 34 (8). — P. 1255-1264.
Stumvoll M., Nurjhan N., Perriello G. et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus // The New England Journal of Medicine. — 1995. — Vol. 333 (9). — P. 550-554.
Loomba R., Lutchman G., Kleiner D.E. et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis // Alimentary Pharmacology and Therapeutics. — 2009. — Vol. 29 (2). — P. 172-182.
Haukeland J.W., Konopski Z., Eggesbø H.B. et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial // Scandinavian Journal of Gastroenterology. — 2009. — Vol. 44 (7). — P. 853-860.
Nar A., Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease // Acta Diabetologica. — Vol. 46 (2). — P. 113-118.
Lavine J.E., Schwimmer J.B., Molleston J.P. et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design // Contemporary Clinical Trials. — 2010. — Vol. 31 (1). — P. 62-70.
Krakoff J., Clark J.M., Crandall J.P. et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program // Obesity. — 2010. — Vol. 18 (9). — P. 1762-1767.